Singapore markets closed

Collegium Pharmaceutical, Inc. (COLL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
31.34-6.52 (-17.22%)
As of 01:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close37.86
Open33.26
Bid23.97 x 200
Ask31.40 x 100
Day's range30.47 - 34.00
52-week range20.83 - 40.95
Volume1,057,432
Avg. volume422,145
Market cap1.025B
Beta (5Y monthly)1.05
PE ratio (TTM)24.30
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Collegium Reports First Quarter 2024 Financial Results

    – Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2024 Guidance – – Conference Call Scheduled for Today at 4:30 p.m.

  • GlobeNewswire

    Collegium Announces CEO Transition

    – Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that effective Ma

  • GlobeNewswire

    Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER

    STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“the Nucynta Franchise”